$39.4 M

BPMX Mkt cap, 20-Sep-2018

$24 K

BioPharmX Revenue Q2, 2019
BioPharmX Gross profit (Q2, 2019)11 K
BioPharmX Gross profit margin (Q2, 2019), %45.8%
BioPharmX EBIT (Q2, 2019)-4.5 M
BioPharmX Cash, 31-Jul-20186.6 M

BioPharmX Income Statement

Annual

USDFY, 2017FY, 2018

Revenue

100 k73 k

Cost of goods sold

516 k250 k

Gross profit

(416 k)(177 k)

Gross profit Margin, %

(416%)(242%)

Sales and marketing expense

3.2 m2.4 m

R&D expense

10.2 m9.1 m

General and administrative expense

4.7 m5.1 m

Operating expense total

18 m16.7 m

EBIT

(18.4 m)(16.9 m)

EBIT margin, %

(18426%)(23118%)

Pre tax profit

(18.4 m)(16.6 m)

Income tax expense

2 k2 k

Net Income

(18.4 m)

Quarterly

USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

5 k20 k33 k19 k33 k19 k18 k18 k24 k

Cost of goods sold

10 k19 k20 k17 k28 k11 k8 k7 k13 k

Gross profit

(5 k)1 k13 k2 k5 k8 k10 k11 k11 k

Gross profit Margin, %

(100%)5%39%11%15%42%56%61%46%

Sales and marketing expense

1.3 m1.3 m1.1 m895 k529 k797 k546 k601 k566 k

R&D expense

1.1 m1.6 m2.2 m3 m2.5 m2.9 m2.1 m2.3 m2.7 m

General and administrative expense

1.1 m930 k1.2 m1.2 m1.2 m1.3 m1.1 m1.4 m1.2 m

Operating expense total

3.6 m3.8 m4.5 m5 m4.2 m5 m3.7 m4.4 m4.5 m

EBIT

(3.6 m)(3.8 m)(4.5 m)(5 m)(4.2 m)(5 m)(3.7 m)(4.4 m)(4.5 m)

EBIT margin, %

(71420%)(19240%)(13515%)(26500%)(12621%)(26489%)(20750%)(24239%)(18612%)

Pre tax profit

(3.8 m)(4.5 m)(5 m)(3.9 m)(5.4 m)(3.7 m)(4.4 m)(4.4 m)

Income tax expense

2 k2 k2 k2 k1 k2 k

BioPharmX Balance Sheet

Annual

USDFY, 2017FY, 2018

Cash

6.5 m7.6 m

Accounts Receivable

4 k7 k

Inventories

38 k10 k

Current Assets

6.8 m8 m

PP&E

120 k109 k

Total Assets

7.1 m8.1 m

Accounts Payable

2.6 m1.4 m

Current Liabilities

3.7 m3 m

Total Liabilities

4.1 m3 m

Additional Paid-in Capital

46 m66.2 m

Retained Earnings

(44.6 m)(61.3 m)

Total Equity

3 m5.1 m

Financial Leverage

2.4 x1.6 x

Quarterly

USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

7.4 m2.2 m4 m436 k468 k6.7 m1.6 m10.9 m6.6 m

Accounts Receivable

33 k9 k6 k1 k7 k3 k8 k5 k16 k

Inventories

364 k336 k76 k112 k77 k30 k15 k6 k13 k

Current Assets

8.2 m2.8 m4.4 m1 m1.3 m7 m2.2 m11.3 m7.3 m

PP&E

226 k224 k205 k204 k185 k118 k123 k158 k141 k

Total Assets

8.6 m3.2 m4.8 m1.4 m1.6 m7.3 m2.4 m11.4 m7.4 m

Accounts Payable

3.3 m1.8 m2.4 m3.4 m2.8 m2.3 m2 m1.8 m1.5 m

Short-term debt

476 k

Current Liabilities

4.3 m2.5 m3.3 m4.5 m5.5 m4.1 m3.7 m3.1 m3.1 m

Total Liabilities

3.8 m3.2 m3.2 m

Additional Paid-in Capital

22.1 m22.4 m32.1 m32.6 m34.5 m50.8 m54.6 m73.7 m74.2 m

Retained Earnings

(17.8 m)(21.7 m)(30.7 m)(39.6 m)(50 m)(57.5 m)(65.7 m)(70.1 m)

Total Equity

4.3 m754 k1.5 m2.4 m(1.3 m)8.2 m4.3 m

Financial Leverage

2 x4.3 x3.3 x3 x-1.8 x1.4 x1.7 x

BioPharmX Cash Flow

Annual

USDFY, 2017FY, 2018

Net Income

(18.4 m)(16.6 m)

Depreciation and Amortization

141 k52 k

Accounts Receivable

3 k(3 k)

Inventories

62 k28 k

Accounts Payable

774 k(1.2 m)

Cash From Operating Activities

(15.7 m)(15.6 m)

Purchases of PP&E

(45 k)(41 k)

Cash From Investing Activities

(45 k)(41 k)

Cash From Financing Activities

18.3 m16.7 m

Income Taxes Paid

2 k2 k

Quarterly

USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2019Q2, 2019

Net Income

(4.4 m)(8.8 m)

Depreciation and Amortization

16 k33 k

Accounts Receivable

33 k9 k6 k1 k7 k3 k2 k(9 k)

Inventories

364 k336 k76 k112 k77 k30 k4 k(3 k)

Accounts Payable

3.3 m1.8 m2.4 m3.4 m2.8 m2.3 m416 k150 k

Cash From Operating Activities

(3.6 m)(7.9 m)

Purchases of PP&E

(4 k)(4 k)

Cash From Investing Activities

(4 k)(4 k)

Cash From Financing Activities

7 m7 m

BioPharmX Ratios

USDY, 2018

Financial Leverage

1.7 x
Report incorrect company information